Final approval of this product is expected upon resolution of patent litigation.
According to Teva, the brand product had annual sales of approximately $3.8 billion in the US for the 12 months that ended September 30, 2008, based on IMS sales data.
Final approval of this product is expected upon resolution of patent litigation.
According to Teva, the brand product had annual sales of approximately $3.8 billion in the US for the 12 months that ended September 30, 2008, based on IMS sales data.